Home | Business News | Browse by Publication | M | M2 Presswire

TwinTrader.com reports on the OTC and OTCBB Trade Leaders: GoFish Corporation (OTCBB: GOFH), Universal Detection Technology (OTCBB: UDTT), ATSI Communications, Inc. (OTCBB: ATSX), Artificial Life, Inc. (OTCBB: ALIF), and Focus Stock of the Day Eugene Science Inc. (OTCBB: EUSI) for December 13, 2007.

Article Excerpt
M2 PRESSWIRE-13 December 2007-TwinTrader: TwinTrader.com reports on the OTC and OTCBB Trade Leaders: GoFish Corporation (OTCBB: GOFH), Universal Detection Technology (OTCBB: UDTT), ATSI Communications, Inc. (OTCBB: ATSX), Artificial Life, Inc. (OTCBB: ALIF), and Focus Stock of the Day Eugene Science Inc. (OTCBB: EUSI) for December 13, 2007.(C)1994-2007 M2 COMMUNICATIONS LTD

RDATE:13122007

To enroll your publicly-traded company in our innovative TwinTrader program, please email feature@TwinTrader.com or call (214) 227-7559 and we will gladly discuss it with you.

TwinTrader Focus Stock for Thursday - Eugene Science Inc. (OTCBB: EUSI) - TwinTrader's Profile Company Trading at $.34

December 12 - Eugene Science Engages Korea Research Institute to Advance Production Level of Its AD/ADD Processing Biotechnology to Commercial Scale

Eugene Science Inc. (OTCBB: EUSI), a leader in the nutraceutical marketplace with its cholesterol lowering CholZero (CZ(TM)) plant sterols, today announced it has engaged the prestigious Korea Research Institute of Bioscience and Biotechnology (KRIBB) to advance the production level of the Company's patented microorganism-based AD/ADD processing biotechnology to commercial scale.

AD/ADD is a key ingredient of steroid hormone medical products such as androgens, estrogens, gestogens, gluco-corticoids, and mineral-corticoids -- and Eugene Science's AD/ADD processing biotechnology is currently well established for manufacturing product at the prototype scale. The Company's process produces significantly higher conversion rates of plant sterols into AD/ADD when compared with conventional chemical synthesis as well as being substantially more cost-effective and environmentally friendly.

"Our AD/ADD microbial conversion production process is vastly superior to existing conventional processes for efficiency and purity," said Seung Kwon Noh, Eugene Science Chairman and Chief Executive Officer. "We use a simpler purification process that enables a greater conversion of sterol to AD/ADD that is only possible with our patented nanotechnology for converting non-soluble sterols into water dispersible sterols. Eugene Science's technology also reduces the cost of production by broadening the limited spectrum of raw materials that can be used to produce AD/ADD from sitosterol only, in conventional processes, to all kinds of plant sterols with our process."

Eugene Science has entered discussions with the leading AD/ADD pharmaceutical producers to market the Company's patented technology, which must be proven to scale efficiently at the one-ton production level to be suitable for commercial applications. The Company expects a formal interim KRIBB report on the AD/ADD processing scale project by the second quarter of 2008, with a final report due in mid 2008.

AD/ADD is a key ingredient for most steroid hormone medical products that have been extensively used in treating...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!